Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
06:04pm, Monday, 06'th Jun 2022 Zacks Investment Research
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patient
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
03:48pm, Monday, 06'th Jun 2022
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patient
AstraZeneca CEO Pascal Soriot breaks down data on new 'transformative' breast cancer drug
11:47am, Monday, 06'th Jun 2022
Pascal Soriot, AstraZeneca CEO, joins 'Squawk on the Street' to discuss why company data around its breast cancer drug was so well received, the next steps for other tumor types and more.
AstraZeneca wows peers but misses out on post-Jubilee bounce
10:45am, Monday, 06'th Jun 2022
AstraZeneca PLC (LSE:AZN) was among the few failing to benefit from the post-Jubilee bounce that sent stocks higher despite unveiling promising results at the weekend for its Enhertu breast cancer t
AstraZeneca's Breast Cancer Drug Beats Expectations, and Other ASCO Highlights
09:31am, Monday, 06'th Jun 2022
The American Society of Clinical Oncology met for its annual conference in Chicago over the weekend.
Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy
04:09pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Apellis (APLS) submits a new drug application to the FDA for pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
Got $5,000? Buy These 2 High-Growth Stocks Before They Soar
02:53pm, Wednesday, 01'st Jun 2022 The Motley Fool
These two companies are leaders in their respective markets.
ASCO Presentations Could Move Shares of Daiichi, AstraZeneca, Gilead and Roche
03:09pm, Tuesday, 31'st May 2022
Investors will want to keep an eye on developments at this week's meeting of the American Society of Clinical Oncology in Chicago, where four members of big pharma will share study results of their mo
The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer
01:39pm, Tuesday, 31'st May 2022 Zacks Investment Research
AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog
Nasal COVID vaccines are being tested in 7 clinical trials -- how would they work?
12:45pm, Tuesday, 31'st May 2022 MarketWatch
3 intranasal vaccines are in Phase 3 human trials.
Here's What AstraZeneca's Recent FDA News Means for Shareholders
12:15pm, Saturday, 28'th May 2022 The Motley Fool
The pharma giant's drug combo is now just months away from potential U.S. approval for a type of liver cancer.
Here's What AstraZeneca's Recent FDA News Means for Shareholders
08:15am, Saturday, 28'th May 2022
The pharma giant's drug combo is now just months away from potential U.S. approval for a type of liver cancer.
3 Unstoppable Stocks That Are Higher Than Before the Market Correction
03:45pm, Friday, 27'th May 2022 The Motley Fool
Market downturns don't affect stocks equally.
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
01:29pm, Friday, 27'th May 2022 Zacks Investment Research
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive
01:07pm, Thursday, 26'th May 2022
Although cancer screening and diagnosis was hit by the coronavirus pandemic, resulting advances in medical technology and greater diversity in clinical trials could help treatments in the future, an A
